CR-CP Life Science Fund

  • New Horizon Health closes USD30m Series E round

    New Horizon Health, China’s first biotech company to focus on early-stage cancer screening, today announced the completion of a 30 million US dollars Series E financing round, led by Rock Springs Capital, with participation from OrbiMed, Rock Springs Capital, Cormorant Asset Management, CR-CP Life Science Fund, Octagon Capital and existing investor Qiming Venture Partners.

  • JW Therapeutics closes USD100m Series B financing round

    JW Therapeutics announced the completion of a US$100 million Series B round of financing, the investment was co-led by CPE and Mirae Asset, jointed by CR-CP Life Science Fund and Oriza Holdings, as well as existing investors including Loyal Valley Capital, Temasek, Sequoia Capital China, ARCH Venture Partners, Juno Therapeutics, a Bristol Myers Squibb company, and WuXi AppTec.

  • Genor Biopharma closes USD160m Series B Round led by Hillhouse Capital

    Genor Biopharma has completed a USD160 million Series B financing round led by existing investor Hillhouse Capital, with participation from new investors Temasek, CR-CP Life Science Fund, Haitong Kaiyuan Investment, and Cavenham PE.